This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Second Genome raises $42.6mm through oversubscribed Series B round; SR One invests additional $8.4mm
25 Jul 2016
Pfizer Venture Investments and Roche Venture Fund co-led a $42.6mm Series B round for Second Genome Inc. (microbiome-based drug discovery for GI and metabolic diseases). The investors also take board seats. Additional participants in the oversubscribed round included new buyers Digitalis Ventures, Adveq, LifeForce Capital, MBL Venture Capital, and the Mayo Clinic, along with Series A investors Advanced Technology Ventures, Morgenthaler Ventures, Seraph Group, and individual investor Matthew Winkler, PhD.
Drug Discovery Tools
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?